NCT06721689 2026-04-15
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
Clinical Trials
16 trialsNCT06995872 2026-04-15
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04901702 2026-04-13
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT06541262 2026-04-09
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT06942039 2026-02-27
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
C17 Council
Phase EARLY_PHASE1 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/IIļ¼Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07375563 2026-01-29
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT07334301 2026-01-12
BEACON2
University of Birmingham
Phase 1/2 Recruiting
NCT05400603 2025-12-26
Aflac-NBL-2002
Emory University
Phase 1 Recruiting
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT07027748 2025-07-14
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting